Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04028401
Other study ID # RC19_0042
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 19, 2020
Est. completion date June 2027

Study information

Verified date November 2023
Source Nantes University Hospital
Contact Stéphane CORVEC
Phone 0240083955
Email stephane.corvec@chu-nantes.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infections on joint replacements remain one of the most serious complications of orthopaedic surgery. Despite improvements in skin preparation and antibiotic prophylaxis procedures, the risk of infection of joint prosthesis is still high, particularly for shoulder prostheses, especially in men. One of the bacteria most often involved in post-operative infections for shoulder prosthesis is Cutibacterium acnes (CA). This bacterium is one of the predominant bacteria in pilosebaceous units. Eradication of this micro-organism remains difficult despite the techniques used in the preoperative phase. The objective of this protocol is to evaluate the efficacy of applying a 5% benzoyl peroxide topical during the 5 days preceding the procedure in the surgical skin incision area, which is based on local acne treatment, on the reduction of the CA bacterial load in the dermis of the approach to shoulder arthroplasty in men.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date June 2027
Est. primary completion date June 2027
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male patients, Adult patients, - Patient without a history of surgical intervention on the operated shoulder, - Patient managed for glenohumeral, partial (cup or anatomical hemi- arthroplasty) or total (anatomical or inverted) glenohumeral arthroplasty placement for primary osteoarthritis, or secondary to necrosis, massive rotator cuff tear or old fracture. - Patients affiliated to a social security system - Patients who have given their informed and written consent Exclusion Criteria: - Patient with arthroplasty for resumption of previous shoulder surgery or failure of arthroplasty - Patient with arthroplasty for acute trauma - Patient on immunosuppressantsimmunosuppressive drugs - Patient with inflammatory rheumatism - Patient with progressive cancer pathology - Allergies or intolerances concerning the modalities of selected skin preparations (Povidone Iodine, hypersensitivity to benzoyl peroxide) - Dermatological pathologies in the area to be treated - Acne treatment in the area to be treated within four weeks before inclusion - Patient without possible help from a third party for the application of Cutacnyl® 5% in the intervention group if necessary - Major under guardianship - Patient under the protection of justice - Patient not covered by social security

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
5% benzoyl peroxide
Application of 5% benzoyl peroxide during 5 days before the procedure

Locations

Country Name City State
France CHU d'Angers Angers
France CHU de Brest Brest
France CHU de Nantes Nantes
France Clinique Saint Michel Sainte Anne Quimper
France CHU de Rennes Rennes
France Institut Locomoteur de l'Ouest Saint-Grégoire
France Santé Atlantique Saint-Herblain
France CHU de Toulouse Toulouse
France CHU de Tours Tours
France CHBA Vannes

Sponsors (1)

Lead Sponsor Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients in each group with a positive Cutibacterium acnes sample at the dermis. Day 0
Secondary Average number of positive intraoperative Cutibacterium acnes samples samples taken at he cutaneous level before and after cutaneous antisepsis of the operating area before incision, fat and capsular. Day 0
Secondary Average number of positive Cutibacterium acnes skin samples before and after alcoholic surgical site antisepsis (5% alcoholic iodine povidone) in each of the two study groups Day 0
Secondary Incidence of Cutibacterium acnes shoulder prosthesis infections up to 2 years after shoulder prosthesis implantation in both study groups 2 years
Secondary Phylotype Determination of phylotype by molecular typing by Multi-Locus Sequence Typing and Single-Locus Sequence Typing techniques and comparison of Cutibacterium acnes strains by molecular biology and characterization of antibiotic resistance Day 0
Secondary Cutibacterium acnes strains Comparison of Cutibacterium acnes strains by molecular biology Day 0
Secondary Antibiotic resistance Day 0
Secondary Evaluation of the skin tolerance of the topical application from the skin tolerance scale (irritation, erythema and desquamation), at the time of inclusion and at D0 skin tolerance scale evaluates local tolerance (absent: 0, light:1, moderate: 2 severe:3), erythema (absent:0, light:1, moderate:2, severe:3, very severe:4) and desquamation (absent: 0, light: 1, moderate: 2, severe: 3, very severe: 4) Day 0